How to improve antibiotic awareness campaigns: findings of a WHO global survey.
World Health Organization
anti-bacterial agents
awareness
bacterial
drug resistance
drug resistance, bacterial
global health
health communication
health education
Journal
BMJ global health
ISSN: 2059-7908
Titre abrégé: BMJ Glob Health
Pays: England
ID NLM: 101685275
Informations de publication
Date de publication:
2019
2019
Historique:
received:
21
10
2018
revised:
15
01
2019
accepted:
19
01
2019
entrez:
11
6
2019
pubmed:
11
6
2019
medline:
11
6
2019
Statut:
epublish
Résumé
We aimed to examine the characteristics of antibiotic awareness campaigns (AAC) conducted on a national or regional level since 2010. In October 2016, the WHO invited stakeholders involved in the planning or conduct of AACs to answer a web questionnaire. We solicited general information about the characteristics of the AAC, with a particular focus on key messages supporting optimal use of antibiotics. Stakeholders in 93 countries were contacted and 55 countries responded. Overall, 60 AACs from 16 low/middle-income countries (LMIC) and 31 high-income countries were identified. Forty-five campaigns (75%) were conducted on a national level and most of them (47/60; 78%) were organised by public health authorities and publicly funded. There were no major differences between LMICs and high-income countries in the types of key messages. The scientifically questionable 'Finish your prescription' slogan was used by 31 AACs (52%). A One Health approach was mentioned in 13/60 AACs (22%). Most messages were universally applicable; adaptation to locally prevalent public misconceptions was not systematic. The evaluation of the impact of campaigns was still incomplete, as only 18 AACs (30%) assessed their impact on antibiotic use. For future AACs, it seems essential to base messages more rigorously on scientific evidence, context specificities and behavioural change theory. A new generation of messages that encourage first-choice use of narrow spectrum antibiotics is needed, reflecting international efforts to preserve broad spectrum antibiotic classes. Evaluation of the impact of AACs remains suboptimal.
Identifiants
pubmed: 31179029
doi: 10.1136/bmjgh-2018-001239
pii: bmjgh-2018-001239
pmc: PMC6528771
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e001239Déclaration de conflit d'intérêts
Competing interests: SH is a temporary member of the speakers’ bureau for Takeda and the scientific advisory boards of DNA Electronics, Sandoz and Bayer. He has received financial support for investigator-initiated research activities from Pfizer.
Références
Infect Control Hosp Epidemiol. 2015 Feb;36(2):142-52
pubmed: 25632996
Eur J Health Econ. 2013 Aug;14(4):587-99
pubmed: 22706960
Expert Rev Anti Infect Ther. 2016;14(4):403-13
pubmed: 26853235
S Afr Med J. 2015 Apr 06;105(5):325
pubmed: 26242647
Health Educ Res. 2009 Jun;24(3):483-95
pubmed: 18948569
Cochrane Database Syst Rev. 2013 Jun 06;(6):CD004704
pubmed: 23744348
Lancet Infect Dis. 2018 Jan;18(1):18-20
pubmed: 29303731
Clin Microbiol Rev. 2013 Apr;26(2):289-307
pubmed: 23554418
BMC Fam Pract. 2016 Nov 3;17(1):148
pubmed: 27809770
Antimicrob Agents Chemother. 2014;58(1):71-7
pubmed: 24126584
J Nutr Educ Behav. 2007 Mar-Apr;39(2 Suppl):S5-12
pubmed: 17336806
JAMA Intern Med. 2016 Sep 1;176(9):1254-5
pubmed: 27455385
JAMA. 2016 Nov 22;316(20):2115-2125
pubmed: 27893129
J Antimicrob Chemother. 2018 Jun 1;73(6):1464-1478
pubmed: 29554263
J Antimicrob Chemother. 2011 Dec;66(12):2872-9
pubmed: 21965428
Curr Opin Pharmacol. 2011 Oct;11(5):446-52
pubmed: 21775205
BMJ. 2017 Jul 26;358:j3418
pubmed: 28747365
Nat Rev Urol. 2017 Mar;14(3):139-152
pubmed: 28072403
J Antimicrob Chemother. 2016 Jan;71(1):27-33
pubmed: 26459555
Lancet Infect Dis. 2010 Jan;10(1):17-31
pubmed: 20129146
Emerg Infect Dis. 2008 Nov;14(11):1722-30
pubmed: 18976555
JAMA. 2016 May 3;315(17):1864-73
pubmed: 27139059
Antimicrob Resist Infect Control. 2016 Oct 20;5:39
pubmed: 27777760
Euro Surveill. 2014 Oct 16;19(41):
pubmed: 25345519
N Engl J Med. 2013 Dec 26;369(26):2474-6
pubmed: 24369073
Clin Microbiol Infect. 2008 Apr;14(4):298-306
pubmed: 18093237
J Antimicrob Chemother. 2017 Apr 1;72(4):975-987
pubmed: 27999058
Cochrane Database Syst Rev. 2011 Dec 07;(12):CD006777
pubmed: 22161408
J Antimicrob Chemother. 2010 Jul;65(7):1526-33
pubmed: 20488985
BMC Public Health. 2014 Jun 18;14:616
pubmed: 24939013
Emerg Infect Dis. 2002 Dec;8(12):1460-7
pubmed: 12498664
BMJ. 2013 Sep 12;347:f5391
pubmed: 24030722
J Antimicrob Chemother. 2017 Jan;72(1):311-314
pubmed: 27655854
BMC Infect Dis. 2015 Nov 25;15:545
pubmed: 26607324
J Antimicrob Chemother. 2018 Jun 1;73(suppl_6):vi17-vi29
pubmed: 29878219
J Med Internet Res. 2015 Oct 15;17(10):e233
pubmed: 26471079
Lancet. 2016 Jan 9;387(10014):176-87
pubmed: 26603922
Cochrane Database Syst Rev. 2017 Feb 09;2:CD003543
pubmed: 28178770
Clin Infect Dis. 2016 Feb 1;62(3):403-4
pubmed: 26433719
N Engl J Med. 2006 Apr 6;354(14):1455-63
pubmed: 16598044
PLoS One. 2014 Aug 27;9(8):e104556
pubmed: 25162505
Proc Biol Sci. 2014 Nov 7;281(1794):20140566
pubmed: 25253451
Curr Drug Saf. 2010 Oct;5(4):329-32
pubmed: 20615180
J Antimicrob Chemother. 2012 Mar;67(3):763-7
pubmed: 22200725
BMJ. 2016 Mar 15;352:i939
pubmed: 26980184
Lancet Infect Dis. 2008 Dec;8(12):785-95
pubmed: 19022193
Clin Infect Dis. 2009 Sep 1;49(5):750-6
pubmed: 19624280
J Health Commun. 2015;20(12):1433-40
pubmed: 26181623
Br J Gen Pract. 2013 Jul;63(612):e429-36
pubmed: 23834879